炎症性腸疾患に対する白血球除去療法 : 臨床成績と今後の展望(<特集>血球成分除去療法の新しい展開)

概要

論文の詳細を見る
Although the precise mechanisms of pathogenesis of inflammatory bowel disease (IBD) remain unclear, previous studies have revealed evidence of the recruitment of circulating leukocytes to the affected bowel. Removal of circulating leukocytes was therefore speculated to be an attractive approach for treating IBD. Trials of therapeutic leukofiltration from the peripheral circulation, otherwise known as leukocytapheresis, have been performed using a veno-venous extracorporeal apheresis device coupled to a leukofiltration column. This review focuses on the clinical efficacy and safety data of leukocytapheresis in IBD. Although the majority of clinical studies enrolled only a small number of patients and were designed as open-labeled trials, leukocytapheresis showed clinical efficacy with an excellent safety profile. Further controlled trials with a larger number of patients would be required to determine efficacy with medical evidence of this approach.
日本アフェレシス学会の論文
2009-02-28